Bisphosphonates in multiple myeloma.

Bisphosphonates as antimyeloma drugs. Leukemia (2011) 0.83

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica (2011) 0.80

Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma. Curr Oncol (2012) 0.78

The multiple oral presentations of multiple myeloma. Support Care Cancer (2013) 0.76

Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy). ISRN Oncol (2013) 0.76

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol (2011) 0.75

A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease. Int J Numer Method Biomed Eng (2015) 0.75

Bone Metastases: An Overview. Oncol Rev (2017) 0.75

Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72

Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 10.99

Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA (2008) 8.20

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood (2010) 7.50

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90

Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med (2012) 5.77

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87

Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer (2007) 4.60

Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ (2004) 4.50

Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med (2013) 4.20

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood (2005) 3.68

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet (2014) 3.44

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol (2013) 2.74

Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2014) 2.63

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55

Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women. Obstet Gynecol (2012) 2.48

Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 2.46

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43

Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19

When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15

Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood (2006) 2.12

Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev (2011) 2.12

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol (2002) 2.01

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol (2009) 1.96

PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child (2011) 1.91

Randomized trials in oncology stopped early for benefit. J Clin Oncol (2008) 1.89

Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol (2007) 1.86

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood (2005) 1.85

Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (2012) 1.80

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol (2003) 1.71

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol (2010) 1.70

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood (2005) 1.70

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med (2002) 1.69

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood (2012) 1.67

When is diagnostic testing inappropriate or irrational? Acceptable regret approach. Med Decis Making (2008) 1.62

Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol (2009) 1.59

Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome. Mycoses (2006) 1.58

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol (2010) 1.57

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood (2007) 1.54

Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.53

Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ (2005) 1.52

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol (2009) 1.52

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant (2009) 1.51

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51

Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol (2005) 1.50

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol (2009) 1.46

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant (2007) 1.45

Do community health worker interventions improve rates of screening mammography in the United States? A systematic review. Cancer Epidemiol Biomarkers Prev (2011) 1.44

NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44

Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol (2011) 1.44

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43

Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis (2005) 1.43

Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol (2005) 1.42

Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42

Medical research: Trial unpredictability yields predictable therapy gains. Nature (2013) 1.41

Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol (2003) 1.41

Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials. Contemp Clin Trials (2012) 1.40

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol (2002) 1.40

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant (2009) 1.40

Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev (2006) 1.40

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36

Lifting the fog of uncertainty from the practice of medicine. BMJ (2004) 1.35

Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ (2012) 1.35

Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34

Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med (2012) 1.34

Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol (2012) 1.32

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 1.30

Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28

New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev (2012) 1.28